Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086
Open Access
- 23 May 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 94 (11) , 1637-1642
Abstract
WEB-2086 – an antagonist of platelet-activating factor receptor (PAFR) with known anti-inflammatory, antiangiogenic and antileukaemic properties – also proved to inhibit the proliferation in human solid tumour cell lines of different histology, and with much higher efficacy than in normal fibroblasts. A detailed analysis of WEB-2086 anticancer activity was then performed focusing on breast adenocarcinoma MCF-7 and MDA-MB-231 cells. WEB-2086-treated cells, either expressing (MCF-7) or unexpressing (MDA-MB-231) the oestrogen receptor (ER)α, underwent a dose-dependent growth arrest (IC50=0.65±0.09 and 0.41±0.07 mM, respectively) and accumulation in G0–G1 phase. WEB-2086 also induced morphological and functional changes typical of mature mammary phenotype including (i) cell enlargement and massive neutral lipid deposition (best accomplished in MCF-7 cells); (ii) decrease in motility and active cathepsin D levels (mainly observed in highly invasive MDA-MB-231 cells). The expression of ERα was neither increased nor reactivated in treated MCF-7 or MDA-MB-231 cells, respectively. WEB-2086-induced differentiation in breast cancer cells involved the upregulation of PTEN, a key tumour suppressor protein opposing tumorigenesis, and was apparently independent of p53, PAFR, peripheral benzodiazepine receptor and ERα status. Overall, WEB-2086 can be proposed as an effective antiproliferative and differentiative agent with interesting translational opportunities to treat breast cancers in support to conventional chemotherapy.Keywords
This publication has 29 references indexed in Scilit:
- WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potentialLeukemia, 2005
- The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.2001
- Estrogen receptor and breast cancerSeminars in Cancer Biology, 2001
- Role of Exogenous and Endogenous Hormones in Endometrial CancerAnnals of the New York Academy of Sciences, 2001
- Chapter 17 Flow cytometric analysis of cell division history using dilution of carboxyfluorescein diacetate succinimidyl ester, a stably integrated fluorescent probe2001
- Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition.2000
- PAF Produced by Human Breast Cancer Cells Promotes Migration and Proliferation of Tumor Cells and Neo-AngiogenesisThe American Journal of Pathology, 2000
- Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overviewClinica Chimica Acta, 2000
- Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant miceProgress in Lipid Research, 2000
- Effects of differentiation‐inducing agents on maturation of human MCF‐7 breast cancer cellsJournal of Cellular Physiology, 1990